- Home
- PAYS vs ACTU Comparison
PAYS vs ACTU Comparison
Compare PAYS & ACTU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PAYS
- ACTU
- Stock Information
- Founded
- PAYS 1995
- ACTU 2015
- Country
- PAYS United States
- ACTU United States
- Employees
- PAYS N/A
- ACTU N/A
- Industry
- PAYS Business Services
- ACTU
- Sector
- PAYS Consumer Discretionary
- ACTU
- Exchange
- PAYS Nasdaq
- ACTU NYSE
- Market Cap
- PAYS 160.1M
- ACTU 162.1M
- IPO Year
- PAYS 1998
- ACTU 2024
- Fundamental
- Price
- PAYS $2.90
- ACTU $9.45
- Analyst Decision
- PAYS Strong Buy
- ACTU
- Analyst Count
- PAYS 3
- ACTU 0
- Target Price
- PAYS $6.17
- ACTU N/A
- AVG Volume (30 Days)
- PAYS 348.4K
- ACTU 47.8K
- Earning Date
- PAYS 11-05-2024
- ACTU 02-21-2025
- Dividend Yield
- PAYS N/A
- ACTU N/A
- EPS Growth
- PAYS 368.11
- ACTU N/A
- EPS
- PAYS 0.14
- ACTU N/A
- Revenue
- PAYS $56,467,600.00
- ACTU N/A
- Revenue This Year
- PAYS $25.57
- ACTU N/A
- Revenue Next Year
- PAYS $13.13
- ACTU N/A
- P/E Ratio
- PAYS $20.91
- ACTU N/A
- Revenue Growth
- PAYS 27.75
- ACTU N/A
- 52 Week Low
- PAYS $2.65
- ACTU $5.51
- 52 Week High
- PAYS $5.59
- ACTU $10.16
- Technical
- Relative Strength Index (RSI)
- PAYS 42.83
- ACTU N/A
- Support Level
- PAYS $2.95
- ACTU N/A
- Resistance Level
- PAYS $3.40
- ACTU N/A
- Average True Range (ATR)
- PAYS 0.19
- ACTU 0.00
- MACD
- PAYS 0.02
- ACTU 0.00
- Stochastic Oscillator
- PAYS 22.31
- ACTU 0.00
About PAYS Paysign Inc.
PaySign Inc is a provider of prepaid card programs, comprehensive patient affordability offerings, digital banking services, and integrated payment processing designed for businesses, consumers, and government institutions. The Company creates customized, payment solutions for clients across industries, including pharmaceutical, healthcare, hospitality, and retail. The company's revenues include fees generated from cardholder fees, interchange, card program management fees, transaction claims processing fees, and settlement income.
About ACTU ACTUATE THERAPEUTICS INC
Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3β, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.